FLT3 and acute myeloid leukemia: However, when comparing the outcome of CN-AML patients with NPM1 mutated/FLT3–ITD negative genotype to those with other genotypes, and according to the randomization arm, we observed that the NPM1 mutated/FLT3–ITD negative genotype was associated with favorable outcome in the control arm (P = 0.04), but not in the GO arm (P = 0.89) (Figure S4).